134 related articles for article (PubMed ID: 15220362)
1. Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma.
Morris MR; Maina E; Morgan NV; Gentle D; Astuti D; Moch H; Kishida T; Yao M; Schraml P; Richards FM; Latif F; Maher ER
J Clin Pathol; 2004 Jul; 57(7):706-11. PubMed ID: 15220362
[TBL] [Abstract][Full Text] [Related]
2. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development.
Clifford SC; Walsh S; Hewson K; Green EK; Brinke A; Green PM; Gianelli F; Eng C; Maher ER
Genes Chromosomes Cancer; 1999 Sep; 26(1):20-8. PubMed ID: 10441001
[TBL] [Abstract][Full Text] [Related]
3. Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma.
Morris MR; Hughes DJ; Tian YM; Ricketts CJ; Lau KW; Gentle D; Shuib S; Serrano-Fernandez P; Lubinski J; Wiesener MS; Pugh CW; Latif F; Ratcliffe PJ; Maher ER
Anticancer Res; 2009 Nov; 29(11):4337-43. PubMed ID: 20032376
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
6. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
[TBL] [Abstract][Full Text] [Related]
7. Mutations of the VHL tumour suppressor gene in renal carcinoma.
Gnarra JR; Tory K; Weng Y; Schmidt L; Wei MH; Li H; Latif F; Liu S; Chen F; Duh FM
Nat Genet; 1994 May; 7(1):85-90. PubMed ID: 7915601
[TBL] [Abstract][Full Text] [Related]
8. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.
Shuin T; Kondo K; Torigoe S; Kishida T; Kubota Y; Hosaka M; Nagashima Y; Kitamura H; Latif F; Zbar B
Cancer Res; 1994 Jun; 54(11):2852-5. PubMed ID: 8187067
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-inducible factor-2alpha mRNA expression in human renal cell carcinoma.
Sandlund J; Ljungberg B; Wikström P; Grankvist K; Lindh G; Rasmuson T
Acta Oncol; 2009; 48(6):909-14. PubMed ID: 19322701
[TBL] [Abstract][Full Text] [Related]
10. VHL and HIF signalling in renal cell carcinogenesis.
Baldewijns MM; van Vlodrop IJ; Vermeulen PB; Soetekouw PM; van Engeland M; de Bruïne AP
J Pathol; 2010 Jun; 221(2):125-38. PubMed ID: 20225241
[TBL] [Abstract][Full Text] [Related]
11. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability.
Isaacs JS; Jung YJ; Mole DR; Lee S; Torres-Cabala C; Chung YL; Merino M; Trepel J; Zbar B; Toro J; Ratcliffe PJ; Linehan WM; Neckers L
Cancer Cell; 2005 Aug; 8(2):143-53. PubMed ID: 16098467
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells.
Harten SK; Esteban MA; Shukla D; Ashcroft M; Maxwell PH
Mol Cancer; 2011 Jul; 10():89. PubMed ID: 21791076
[TBL] [Abstract][Full Text] [Related]
13. Loss of PL6 protein expression in renal clear cell carcinomas and other VHL-deficient tumours.
Ivanova AV; Vortmeyer A; Ivanov SV; Nickerson ML; Maher ER; Lerman MI
J Pathol; 2008 Jan; 214(1):46-57. PubMed ID: 17973242
[TBL] [Abstract][Full Text] [Related]
14. Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility.
Astuti D; Ricketts CJ; Chowdhury R; McDonough MA; Gentle D; Kirby G; Schlisio S; Kenchappa RS; Carter BD; Kaelin WG; Ratcliffe PJ; Schofield CJ; Latif F; Maher ER
Endocr Relat Cancer; 2011 Feb; 18(1):73-83. PubMed ID: 20959442
[TBL] [Abstract][Full Text] [Related]
15. Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion.
Sudarshan S; Shanmugasundaram K; Naylor SL; Lin S; Livi CB; O'Neill CF; Parekh DJ; Yeh IT; Sun LZ; Block K
PLoS One; 2011; 6(6):e21037. PubMed ID: 21695080
[TBL] [Abstract][Full Text] [Related]
16. Pseudohypoxic pathways in renal cell carcinoma.
Bratslavsky G; Sudarshan S; Neckers L; Linehan WM
Clin Cancer Res; 2007 Aug; 13(16):4667-71. PubMed ID: 17699843
[TBL] [Abstract][Full Text] [Related]
17. Re: Inactivation of the PBRM1 Tumor Suppressor Gene Amplifies the HIF-Response in VHL
Atala A
J Urol; 2017 Oct; 198(4):746-748. PubMed ID: 28905789
[No Abstract] [Full Text] [Related]
18. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.
Ooi A; Wong JC; Petillo D; Roossien D; Perrier-Trudova V; Whitten D; Min BW; Tan MH; Zhang Z; Yang XJ; Zhou M; Gardie B; Molinié V; Richard S; Tan PH; Teh BT; Furge KA
Cancer Cell; 2011 Oct; 20(4):511-23. PubMed ID: 22014576
[TBL] [Abstract][Full Text] [Related]
19. The genetic basis of kidney cancer: a metabolic disease.
Linehan WM; Srinivasan R; Schmidt LS
Nat Rev Urol; 2010 May; 7(5):277-85. PubMed ID: 20448661
[TBL] [Abstract][Full Text] [Related]
20. Kidney tumors associated with germline mutations of FH and SDHB show a CpG island methylator phenotype (CIMP).
Ricketts CJ; Killian JK; Vocke CD; Wang Y; Merino MJ; Meltzer PS; Linehan WM
PLoS One; 2022; 17(12):e0278108. PubMed ID: 36455002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
